{"entity":{"id":"nct04395677","kind":"trial","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","aka":[],"tldr":"A phase 2 trial of AB-106 in non-small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.","summary":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene is a phase 2 interventional study registered as NCT04395677 by Nuvation Bio Inc., with 173 participants enrolled, started 2020-07-07 and due to reach its primary completion in 2024-06-07. Interventions recorded: AB-106.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04395677","url":"https://clinicaltrials.gov/study/NCT04395677"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nuvation-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04395677","phase":"2","setting":"A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC","sponsor":"Nuvation Bio Inc.","enrolled":173,"outcomes":[]},"route":"/trials/nct04395677/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/"}]}}